These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
201 related articles for article (PubMed ID: 21882254)
1. PAX3-FOXO1 and FGFR4 in alveolar rhabdomyosarcoma. Marshall AD; van der Ent MA; Grosveld GC Mol Carcinog; 2012 Oct; 51(10):807-15. PubMed ID: 21882254 [TBL] [Abstract][Full Text] [Related]
2. PAX3-FOXO1 induces cannabinoid receptor 1 to enhance cell invasion and metastasis. Marshall AD; Lagutina I; Grosveld GC Cancer Res; 2011 Dec; 71(24):7471-80. PubMed ID: 22037868 [TBL] [Abstract][Full Text] [Related]
3. FGFR4 blockade exerts distinct antitumorigenic effects in human embryonal versus alveolar rhabdomyosarcoma. Crose LE; Etheridge KT; Chen C; Belyea B; Talbot LJ; Bentley RC; Linardic CM Clin Cancer Res; 2012 Jul; 18(14):3780-90. PubMed ID: 22648271 [TBL] [Abstract][Full Text] [Related]
4. Modeling of the human alveolar rhabdomyosarcoma Pax3-Foxo1 chromosome translocation in mouse myoblasts using CRISPR-Cas9 nuclease. Lagutina IV; Valentine V; Picchione F; Harwood F; Valentine MB; Villarejo-Balcells B; Carvajal JJ; Grosveld GC PLoS Genet; 2015; 11(2):e1004951. PubMed ID: 25659124 [TBL] [Abstract][Full Text] [Related]
5. Phosphorylation of serine 205 by the protein kinase CK2 persists on Pax3-FOXO1, but not Pax3, throughout early myogenic differentiation. Dietz KN; Miller PJ; Hollenbach AD Biochemistry; 2009 Dec; 48(49):11786-95. PubMed ID: 19904978 [TBL] [Abstract][Full Text] [Related]
6. Identification of serines 201 and 209 as sites of Pax3 phosphorylation and the altered phosphorylation status of Pax3-FOXO1 during early myogenic differentiation. Dietz KN; Miller PJ; Iyengar AS; Loupe JM; Hollenbach AD Int J Biochem Cell Biol; 2011 Jun; 43(6):936-45. PubMed ID: 21440083 [TBL] [Abstract][Full Text] [Related]
7. Regulation of target genes of PAX3-FOXO1 in alveolar rhabdomyosarcoma. Ahn EH Anticancer Res; 2013 May; 33(5):2029-35. PubMed ID: 23645752 [TBL] [Abstract][Full Text] [Related]
8. PLK1 phosphorylates PAX3-FOXO1, the inhibition of which triggers regression of alveolar Rhabdomyosarcoma. Thalhammer V; Lopez-Garcia LA; Herrero-Martin D; Hecker R; Laubscher D; Gierisch ME; Wachtel M; Bode P; Nanni P; Blank B; Koscielniak E; Schäfer BW Cancer Res; 2015 Jan; 75(1):98-110. PubMed ID: 25398439 [TBL] [Abstract][Full Text] [Related]
9. Helicase CHD4 is an epigenetic coregulator of PAX3-FOXO1 in alveolar rhabdomyosarcoma. Böhm M; Wachtel M; Marques JG; Streiff N; Laubscher D; Nanni P; Mamchaoui K; Santoro R; Schäfer BW J Clin Invest; 2016 Nov; 126(11):4237-4249. PubMed ID: 27760049 [TBL] [Abstract][Full Text] [Related]
10. PAX3-FOXO1 is essential for tumour initiation and maintenance but not recurrence in a human myoblast model of rhabdomyosarcoma. Pandey PR; Chatterjee B; Olanich ME; Khan J; Miettinen MM; Hewitt SM; Barr FG J Pathol; 2017 Apr; 241(5):626-637. PubMed ID: 28138962 [TBL] [Abstract][Full Text] [Related]
12. PAX3-FOXO1 drives miR-486-5p and represses miR-221 contributing to pathogenesis of alveolar rhabdomyosarcoma. Hanna JA; Garcia MR; Lardennois A; Leavey PJ; Maglic D; Fagnan A; Go JC; Roach J; Wang YD; Finkelstein D; Hatley ME Oncogene; 2018 Apr; 37(15):1991-2007. PubMed ID: 29367756 [TBL] [Abstract][Full Text] [Related]
13. Secreted Frizzled-Related Protein 3 (SFRP3) Is Required for Tumorigenesis of PAX3-FOXO1-Positive Alveolar Rhabdomyosarcoma. Kephart JJ; Tiller RG; Crose LE; Slemmons KK; Chen PH; Hinson AR; Bentley RC; Chi JT; Linardic CM Clin Cancer Res; 2015 Nov; 21(21):4868-80. PubMed ID: 26071485 [TBL] [Abstract][Full Text] [Related]
14. Loss of MST/Hippo Signaling in a Genetically Engineered Mouse Model of Fusion-Positive Rhabdomyosarcoma Accelerates Tumorigenesis. Oristian KM; Crose LES; Kuprasertkul N; Bentley RC; Lin YT; Williams N; Kirsch DG; Linardic CM Cancer Res; 2018 Oct; 78(19):5513-5520. PubMed ID: 30093562 [TBL] [Abstract][Full Text] [Related]
15. Acquisition of an oncogenic fusion protein serves as an initial driving mutation by inducing aneuploidy and overriding proliferative defects. Loupe JM; Miller PJ; Bonner BP; Maggi EC; Vijayaraghavan J; Zabaleta J; Taylor CM; Tsien F; Crabtree JS; Hollenbach AD Oncotarget; 2016 Sep; 7(39):62814-62835. PubMed ID: 27588498 [TBL] [Abstract][Full Text] [Related]
17. Alveolar rhabdomyosarcoma: is the cell of origin a mesenchymal stem cell? Charytonowicz E; Cordon-Cardo C; Matushansky I; Ziman M Cancer Lett; 2009 Jul; 279(2):126-36. PubMed ID: 19008039 [TBL] [Abstract][Full Text] [Related]
18. Small molecule inhibition of PAX3-FOXO1 through AKT activation suppresses malignant phenotypes of alveolar rhabdomyosarcoma. Jothi M; Mal M; Keller C; Mal AK Mol Cancer Ther; 2013 Dec; 12(12):2663-74. PubMed ID: 24107448 [TBL] [Abstract][Full Text] [Related]
19. A Fusion Transcription Factor-Driven Cancer Progresses to a Fusion-Independent Relapse via Constitutive Activation of a Downstream Transcriptional Target. Boudjadi S; Pandey PR; Chatterjee B; Nguyen TH; Sun W; Barr FG Cancer Res; 2021 Jun; 81(11):2930-2942. PubMed ID: 33589519 [TBL] [Abstract][Full Text] [Related]
20. Structural and functional studies of FKHR-PAX3, a reciprocal fusion gene of the t(2;13) chromosomal translocation in alveolar rhabdomyosarcoma. Hu Q; Yuan Y; Wang C PLoS One; 2013; 8(6):e68065. PubMed ID: 23799156 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]